ASCO 2022 Conference Coverage


 

ASCO 2022 on a Phase 1b Study of Blinatumomab With the Anti-Programmed Cell Death PD-1 Antibody AMG 404 in Adults With R/R B-Cell Precursor ALL

15 views
June 17, 2022
Comments 0
Login to view comments. Click here to Login